The University of California, San Diego (UCSD) was awarded a $2,179,391 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct proof-of-concept preclinical studies and GMP development of AAV-SynCav1 gene technology to treat amyotrophic lateral sclerosis (ALS). The award, which began on May 1, 2024, will support research and development efforts aimed at advancing a novel gene therapy approach to address this debilitating neurological condition. As a leading public research university, UCSD will leverage its expertise in areas like neuroscience, engineering, and biomedical research to drive the progression of this innovative therapy from the preclinical stage towards potential clinical trials and future implementation. The federal grant award will enable UCSD to undertake critical steps in the product development lifecycle, including proof-of-concept studies and good manufacturing practice (GMP) development, in order to ultimately deliver an effective treatment option for individuals suffering from ALS.
Generated 1/28/25, 10:42 AM